Journal of the Neurological Sciences

PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers

Retrieved on: 
Monday, December 19, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Lymphatic system, PAM, Annual report, Patient, U.S. FDA, Journal of the Neurological Sciences, Monash University, Benzodiazepine, University of Melbourne, Disorder, Liver, Immune system, Journal, Environment, Depression, Evaluation, Angewandte Chemie, Kathryn Bullock, PRTC, Drug development, Pharmacy, Allopregnanolone, FDA, Safety, Clinical trial, PPD, LSE, CDER, GABA, Multimedia, Fat, Food, PureTech Health, Pharmacology, Parkinson's disease, Monash Institute of Medical Research, Therapy, Journal of Controlled Release, Platform supply vessel, GABAA, Research, Control, Pharmaceutical industry, Vaccine, CBD, Glyph, List of Nature Research journals

View the full release here: https://www.businesswire.com/news/home/20221219005209/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221219005209/en/
    PureTech announced topline results for LYT-300 (oral allopregnanolone), a therapeutic candidate in development for neurological and neuropsychological conditions.
  • The results show that oral administration of LYT-300 achieved blood levels of allopregnanolone at or above those associated with therapeutic benefit and results in exposure-dependent target engagement of GABAA receptors.
  • The impact of LYT-300 on b-EEG and other markers of GABAA target engagement were also assessed.
  • PureTech completed a Phase 1 clinical trial of LYT-300 in 2022, which demonstrated oral bioavailability, tolerability and GABAA receptor target engagement in healthy volunteers.

Severely Stressful Events Worsen Symptoms of Long COVID

Retrieved on: 
Wednesday, November 9, 2022
Trauma, NYU Langone Health, Yale School of Medicine, Cognition, NYU, Frontera, Anxiety, Ageing, Journal of the Neurological Sciences, PLOS, Hospital, Patient, PLOS One, JNS, Department, Brookings Institution, Brain, Population, Death, Mid-Columbia Medical Center, New York University Grossman School of Medicine, Sleep, Brookings, Journal, Montreal, Occupational therapy, Headache, Brown University School of Public Health, COVID-19, Food, Degenerative disease, COVID, Disability, NIH, Department of Neurology, Xuanwu hospital, Fatigue, Barthel scale, Depression, Montreal Cognitive Assessment, Woman, Rankine scale, MRS, Research, Quality of life, Risk, Adult, Pharmaceutical industry, Medical device, Neurology, MD

"Therapies that lessen the trauma of the most stress-inducing life events need to be a central part of treatment for long COVID, with more research needed to validate the best approaches."

Key Points: 
  • "Therapies that lessen the trauma of the most stress-inducing life events need to be a central part of treatment for long COVID, with more research needed to validate the best approaches."
  • Because there is no current biological definition long COVID, many studies lump disparate symptoms into what is currently a blanket diagnosis, and without an assessment of clinical relevance, says Frontera.
  • The most severely affected patients had higher rates of disability, worse measures of anxiety, depression, fatigue and sleep disorders.
  • The Brookings Institution estimated in August 2022 that roughly 16 million working-age Americans (aged 18 to 65) have long COVID, out of which 2 to 4 million are out of work due to long COVID.

COVID-19: Cytokine Storm and Coagulopathy Markers Controlled With Nichi Glucan Variants; The First of Its Kind Report in a Clinical Study

Retrieved on: 
Tuesday, October 12, 2021
Health, Infectious Diseases, Fitness & Nutrition, Clinical Trials, Research, Science, Biotechnology, COVID-19, Symbiosis, Brain, Trial of the century, Criterion, Nichi, Journal, Interleukin 6, CD8, Fungus, R, Multimedia, C-reactive protein, Safety, Immunomodulation, Microglia, Health, CD4, Immune system, Coagulopathy, LCR, Patient, NLR, Journal of the Neurological Sciences, Research, Immunity, Biomarker, Pharmaceutical industry, Vaccine

Cytokine storm and coagulopathy, the major life-threatening complications of COVID-19, whose biomarkers Interleukin-6 and D-Dimer were under control with consumption of two variants of Nichi Glucan food supplements from Japan in a pilot study.

Key Points: 
  • Cytokine storm and coagulopathy, the major life-threatening complications of COVID-19, whose biomarkers Interleukin-6 and D-Dimer were under control with consumption of two variants of Nichi Glucan food supplements from Japan in a pilot study.
  • (Graphic: Business Wire)
    The Covid-19 infection by SARS-COV-2 virus leads to several complications and those have succumbed to the illness developed cytokine storm because of an overreacting immune system, that should be tackled with immunomodulation.
  • Their combination has yielded this encouraging outcome and our interpretations are based on the present study as well as pre-clinical and clinical studies in healthy volunteers, he added ( https://doi.org/10.1101/2021.08.05.21261640 ).
  • In the 1980s, evolution inspired, Prof Noboru Fujii started exploring this poly-extremo tolerant fungus, that was nature gifted.